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Abstract 
Field effect transistors (FETs) are solid-state electrical devices with semiconductor channels 
through which charge carriers migrate and generate current.  The application of an electric field 
proximal to the conductive channel causes a change in current depending on the sign and 
magnitude of the field.  FETs can be modified for protein sensing by deployment of antibodies as 
receptors on the channel surface to create an immunologically modified FET (immunoFET).  
Binding of analytes brings a layer of charge proximal to the channel surface, causing modulation 
of current that is easily detectable, allowing for quantitative detection of unlabeled analytes.  The 
FET design may be scalable to allow for inexpensive, real-time, label-free, point-of-care 
diagnostic use.   The distance between the analyte and the channel is crucial as sensitivity drops 
off due to counter-ion shielding, which historically was the reasoning behind assessing 
immunoFETs as infeasible.  Bound proteins must therefore be held within a couple nanometers 
of the channel for successful detection.  Following previous work showing successful detection 
of various analytes in PBS, we present the successful detection of Monokine induced by 
Interferon γ (MIG/CXCL9), a pro-inflammatory chemoattractant chemokine, in both murine 
serum and human urine from transplant patients using AlGaN/GaN heterojunction FETs 
(HFETs) modified with anti-CXCL9 IgG.  ImmunoHFETs were modified with IgG antibodies 
specific to CXCL9 then exposed to human urine of renal transplant recipients.  Baselines and 
changes in conductance were compared to determine levels of CXCL9 in clinical samples.  We 
present the detection of CXCL9 in renal transplant urine at biologically relevant levels and 
correlated with rejection by renal biopsy.  The presented work demonstrates the feasibility of 
immunoHFET sensor operation in physiologic buffers, and shows the potential to provide real-
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time quantification and monitoring of inflammatory mediators, allowing for low-cost and 
minimally invasive real-time interrogation of graft status.   
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Introduction 
Motivation for Biosensing 
Proteins, which have influence over innumerable processes in nature, are involved in host 
responses to a wide variety of disease formation and defense in the human body.  For this reason, 
it can be diagnostically significant to identify the concentrations of key proteins and may also 
facilitate the staging of disease progression.  Along with many diseases, various pathological 
immuno-inflammatory states may also be identified by monitoring a specific family of protein 
molecules called cytokines.  These small molecules (5-20kDa) are known to be heavily involved 
in cell signaling within the immune system and therefore, a great deal of effort has been directed 
towards better understanding proteins within these pathways [5].  
Currently, protein detection and quantification is accomplished by enzyme-linked 
immunosorbent assay (ELISA), western blot, bicinchoninic acid assay (BCA), etc. and while 
effective, these techniques require large quantities of costly reagents and are also time and labor 
intensive.  As potentially pivotal devices in the clinic, biosensors have the ability to monitor 
disease prior to the development of symptoms by quantifying concentrations of specific proteins 
in an inexpensive and timely manner.   
As depicted in Figure 1, biosensors incorporate the use of a bioelement for specific 
recognition of an analyte (typically an enzyme or antibody) as well as a transducer to convert the 
binding event into a readable signal (potentially a temperature, conductance, potential, current, or 
impedance).  Transducers used within biosensors can be as diverse as semiconductor or 
cantilever based devices.  
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 Figure 1: Biosensor technology. 
 
Field Effect Transistors as Biosensors 
Typical field effect transistors (FETs) are three-terminal solid-state electrical devices 
consisting of a source and drain, which are biased to drive current flow, and a gate, used to 
modulate the current through the application of a bias proximal to the conductive channel. The 
bias produces an electrical field, which effects charge carrier flow and causes either an increase 
or decrease in current depending on the sign of the field.   
As in metal oxide semiconducting FETs (MOSFETs), the gate allows for current flow if 
above (for n-type) or below (for p-type) the threshold voltage.  The n-type FET, which utilizes 
electrons as charge carriers, will be discussed from this point on for the purposes of this research.  
As the bias is altered above the threshold voltage, more charge carriers are drawn into the 
channel from the doped wells and the device current increases whereas when the gate bias moves 
closer to the threshold voltage, fewer charge carriers are drawn into the channel and the current 
is decreased. 
As biosensors, FETs utilize a biological affinity element deployed on the sensing surface 
to bind the analyte of interest and hold it in close proximity.   The charge of the bound analyte 
then imparts an electric field which alters current flow throughout the conducting channel.  The 
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change in current within the channel is measured and correlated to a concentration of the specific 
analyte in solution.  FET-based sensors have been studied extensively since the creation of the 
ion sensitive FET (ISFET) by Bergveld, et. al. in 1970.   Basic ISFET operation is broadly 
similar to that of MOSFETs except that the gate on the capacitance layer is replaced by enzymes 
as the affinity elements whose ions provide the current modulation [9,10].   
The operational properties of FET biosensors provide potential advantages for protein 
sensing/detection, including label-free detection, high sensitivity, rapid response, convenient size 
scalability, and low fabrication costs.  By being based on intrinsic properties of analytes, FET 
biosensors are also platforms for label-free detection.  FET biosensors may lead to minimally-
invasive point-of-care diagnostics that are faster and less expensive than currently used 
immunoassay or biopsy. 
 
Classical ImmunoFET Model 
The distance between the analyte and the sensing channel is crucial as sensitivity drops 
off to 6th the power of distance due to counter-ion shielding that occurs in high ionic 
concentrations (150nM Na+, pH 7.4), which historically was the reasoning behind assessing the 
possibility of an immunoFET as infeasible [12].  The distance from the sensing channel for 
which electrostatic effects persist, the Debye length, is on the order of a few nanometers when 
working in PBS meaning that beyond this, mobile ions screen out the electric fields of the bound 
analytes.  The classical assessment asserts that the bound analyte will be at a distance equal to 
the length of an antibody (10-15nm for chemokines) from the sensing surface and thus beyond 
the Debye length [9, 10].   
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This model hinges on the idea that antibodies uniformly adsorb onto the sensing surface 
by the CH3 region (Figure 3) and orient in a manner that positions the variable domains of the 
antibody at a distance further than the Debye length.  This is represented in Figure 2a, however a 
more realistic depiction of antibody alignment on an immunoFET can be seen in Figure 2b [7].  
Antibodies are known to adsorb to surfaces in a non-uniform manner as shown.  
 
Figure 2: (a) Classical representation of antibodies (Y shapes) deployed on an immunoFET surface. 
Approximate Debye length position is indicated by the dashed line.  (b) A more realistic depiction of antibody 
alignment on an immunoFET. Adapted from Casal, et. al. [7] 
 
The classical assessment also assumes that antibodies are rigid structures when in fact 
they are highly flexible.  Figure 3 depicts a simplified IgG molecule consisting of four 
polypeptide chains held together by disulfide bonds.  Antigen binding is mediated by the variable 
light (VL) and variable heavy (VH) regions while common effector functions are controlled by 
the constant regions of the antibody.  The portions of the antibody that add to the flexibility 
include the hinge region (the disulfide linkages between constant region 1 and constant region 2) 
as well as the molecular ball-and-socket region between variable and constant domains.  These 
regions create a large degree of conformational freedom allowing for bending and thus a wide 
range of distances over which the bound analyte charges can be held from the semiconducting 
surface. 
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 Figure 3: Simplified depiction of IgG Antibody. Adapted from Casal, etl al. [7] 
 
When taken together, the stochastic adsorption along with the flexibility of antibodies 
leads to a distribution of distances over which the bound analyte charges are held from the 
sensing surface.  A portion of these charges are expected to be within the Debye length in 
physiological conditions.  This indicates that charges may be held in close enough proximity to 
cause current modulation from source to drain, thus deeming the classical assessment as 
inconsequential to the development of an immunoFET.  
 
Research Focus and Significance 
Provided the theoretical flaws of the classical model of immunoFET function and 
previous work for detection of various analytes in PBS, the fundamental goal of this work was to 
develop immunoFET devices for use in physiological solution.  Preliminary results for 
immunoFET function in PBS have been published showing that signal magnitude for a fixed 
analyte charge is directly related to charge proximity to the sensing channel [7, 28].  The work 
presented herein focuses on the development and testing of an immunologically modified field 
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effect transistor for detection of the pro-inflammatory chemokine Monokine induced by 
Interferon γ (MIG/CXCL9) in physiological solution.  As a chemoattractant for cytotoxic T-cells, 
MIG increases during inflammatory responces from the normal concentrations of 40-100pM to 
1-2 orders of magnitude higher, indicating the onset of acute inflammatory response.  The 
monitoring of MIG concentrations in transplant recipients can be used as an early indicator of 
allograft rejection [3, 4].   
This study completed device and ELISA testing for renal transplant recipient urine 
samples in an effort to further the progress towards the development of an immunoFET for real-
time quantification and monitoring of inflammatory mediators, allowing for minimally invasive 
interrogation of graft status.   
 
Background 
HFET Biosensor Development 
FETs are traditionally constructed from silicon-based substances, due to the low-cost and 
high performance, and also doped with impurities that donate mobile electrons for conduction.  
However, in physiological salt conditions (150mM NaCl), ions leach into this silicon substrate 
causing changes in the device performance.  In order to avoid this, an ion-impermeable 
heterojunction FET (HFET) platform made of wide-bandgap materials AlGaN/GaN was 
developed.  This technology also allows for the exclusion of doped wells and the gate terminal of 
MOSFETs.  This is possible because the junction between AlGaN (the highly doped supply 
layer) and GaN (non-doped layer) creates a 2-dimensional electron gas (2DEG) sensitive to 
changes in the electric potential (Figure 4).  Dipole moments are introduced along the Ga-N and 
Al-N bonds due to strong electronegativity of Nitrogen.   
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HFETs can be modified to allow for protein sensing by deployment of affinity elements 
(antibodies) as receptors on the semiconducting channel surface to create an immunologically 
modified HFET (immunoHFET).  Binding of analytes to receptors brings a layer of charge 
proximal to the channel surface, causing modulation of current that is easily detectable and 
allowing for quantitative detection of unlabeled analytes.   
 
 
Figure 4: immunoHFET device cross-section. 
 
Detection of Various Analytes in PBS 
Monokine induced by Interferon γ (MIG/CXCL9) was and continues to be the primary 
protein of interest for this work.  In previously published works, it has been shown that 
immunoHFETs have the ability to detect human and murine CXCL9 in PBS [7].  Detection has 
also been extended to analytes of varying sizes and charges including Chemokine Ligand 5 
(CCL5), also known as RANTES (Regulated upon Activated, Normal t-cell Expressed, and 
Secreted), as well as CXCL10 and streptavidin (SA) in PBS [28].  It has been shown that the 
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immunoHFET has the ability to detect relatively small proteins of positive charge as well as 
larger proteins of negative charge: CCL5 (7.8kDa, +5), CXCL9 (11.7kDa, +14), CXCL10 
(8.6kDa, +11), and SA (76kDa, -6).  A protein has yet to be encountered that is not detectable by 
immunoHFET technologies.   All sensor testing was corroborated by ELISA utilizing a kit 
purchased from R & D Systems (Minneapolis, MN).   
 
ImmunoHFET Selectivity 
In previously published works, it has been shown that immunoHFETs have the ability to 
selectively bind exceedingly similar analytes in PBS.  Shown by Casal, et. al, when 
functionalized with anti-huMIG antibodies, huMIG was detected  but murine MIG was not as 
seen in Figure 5 [7, 28].  The mature proteins of huMIG and muMIG have similar amino acid 
lengths (103 vs. 105 respectively) with 72% amino acid sequence homology.  This work 
demonstrates that device signal is driven by receptor specificity i.e. device specificity is 
determined by the binding specificity of the receptor deployed on the sensing channel.   
 
 
Figure 5: Anti-huMIG IgG Functionalized immunoHFET specificity determined by receptor.  
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 Experimental Procedures 
Chemicals 
Polyclonal anti-huMIG IgG and a Human MIG ELISA Development Kit were purchased 
from Peprotech, Inc. (Rocky Hill, NJ). Triethoxysilane aldehyde (TEA) was purchased from 
United Chemical Technologies (Bristol, PA) to be used as the silane polymer.  Steptavidin (SA) 
conjugated to horseradish peroxidase (SA-HRP) and Dulbecco’s phosphate-buffered saline 
(PBS) containing 150mM NaCl with a pH of 7.4 are from Invitrogen, Inc. (Carlsbad, CA).  
 
HFET Device Construction 
 As previously published, AlGaN/GaN heterostructures were purchased from CREE, Inc. 
(Raleigh, NC) and underwent several microfabrication processing techniques (Figure 6).  Dry 
MESA etching was used to remove the exposed AlGaN region prior to electrode pattern 
photolithography and metal deposition for placement of electrodes.  A silicone insulator was then 
placed over the electrodes to isolate them from the sensing channel.  
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 Figure 6: AlGaN/GaN HFET Microfabrication Process 
 
The devices were surface oxidized via inductively coupled plasma treatment (ICP) in an 
Anatech 600 oxygen plasma chamber for 30 seconds (75Watts, 700mTorr) [5, 8, 7, 22].  One 
hundred micrometers of the AlGaN layer were recessed in a chloride based ICP so that the 
threshold voltage of the device was shifted to the -0.5V to +0.5V range [7, 28].  The conducting 
channel varied from 50µm to 100µm in width and length with a fluid reservoir height of 10-
20µm.  As described previously, the electrical conductivity between the drain and source was 
controlled by a chemical gate, formed on the oxide and functionalized with antibodies as 
receptors for specific analyte recognition.   
 
Transistor Surface Functionalization and Receptor Exposure 
Surface functionalization of oxidized AlGaN/GaN HFETS was accomplished by 
following protocol for APTES deposition but exposing devices to 5% TEA in ethanol overnight 
within a 50ºC water bath [21].  After a triple rinse in ethanol, devices were treated with 1µg ml-1 
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of receptor anti-huMIG IgG for 1 hour at 37ºC.  The device was then triple rinsed in PBS and 
Tween 20 (0.05%) prior to sample exposure and electrical measurements. 
 
Electrical Measurements and Sample Exposure 
 As previously described, three-terminal (source, drain, and gate) current-voltage 
characteristics of AlGaN/GaN HFETs were measured using an Agilent 4156C semiconductor 
parameter analyzer at room temperature.  The Ids was modulated by the gate bias to the order of 
1µA·mm-1 for detection.  This was done to ensure that the device was operating in the 
subthreshold regime in order to maximize sensitivity [22].  The baseline measurement was first 
taken for the device by exposing to PBS only.  The device was then incubated for 5 minutes 
in15µl of human renal transplant recipient urine at the time of diagnostic renal transplant biopsy, 
after which devices were washed three rounds in PBS.  The Ids was then measured for a second 
time and the changes in Ids before and after analyte binding showed how the device behavior was 
altered by the analyte binding event [5].  
 
Immunosorbent Assay 
Enzyme-linked immunosorbent assays (ELISAs) were performed to corroborate electrical 
sensor data with anti-huMIG.  The 96-well Nunc Maxisorb ELISA plates were incubated with 
1µg ml-1 capture antibody anti-huMIG overnight then blocked with sterile filtered 1% bovine 
serum albumin (BSA) in PBS for 1h before exposure to 100µl of standards and samples for 2h.  
Standards ranging from 10 to 5000 pg/ml along with a background (no primary antibody) and 
negative control (PBS only) were used for comparison.  Wells were then exposed to the detection 
antibody anti-huMIG for 2h prior to incubating with avidin-HRP Conjugate (1:2000 in diluent) 
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for 30 minutes.  Wells were rinsed four times with 0.05% Tween-20 in PBS after each previous 
step and then incubated with ABTS liquid substrate solution for 15 minutes.   The stop solution 
of 1% sodium dodecyl sulfate (SDS) was added and the absorbances of the reacted solutions 
were measured in the Victor X3 Plate Reader at 405nm.  
 
Results 
All data was collected from testing done on the same immunoHFET sensor.  We have 
provided preliminary results for immunoHFETs operating in physiological solution, using an 
ion-impermeable platform (AlGaN/GaN HFET) and show signal magnitude for a fixed analyte 
charge to be directly related to charge proximity to the sensing channel [7].  In work described 
herein, we have presented the successful detection of the inflammatory chemokine CXCL9 in 
both murine serum and human renal transplant patient urine using immunoHFET modified with 
anti-huMIG.  The presented work demonstrates preliminary results of the feasibility of 
immunoHFET sensor operation in physiologic buffers as an early step in the translation of this 
technology to human clinical applications.  Many opportunities for increased sensitivity and 
optimization exist for this device, which will be further investigated.   
 
Detection of CXCL9 in Murine Serum 
 After detection of huMIG in PBS, preliminary studies were completed for detection of 
huMIG in a complex physiologic buffer of murine serum [28].  Murine serum, a much higher 
sample fluid complexity as compared to PBS, contains all proteins not used in coagulation as 
well as hormones, electrolytes, and various antibodies and antigens.  Murine serum was doped 
with 100ng/ml of huMIG.  Anti-huMIG functionalized immunoHFETs were incubated with 1% 
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BSA sterile filtered in PBS for 1 hour in order to block non-specific binding.  Three-terminal 
current-voltage characteristics were measured as described previously.   Figure 7 shows the 
electrical measurements for baseline (PBS only), undoped murine serum, as well as murine 
serum doped with huMIG.  These results act to provide proof of concept that the immunoHFET 
has the ability to detect huMIG in a complex physiological solution, murine serum.   
 
 
Figure 7: ImmunoHFET detection of huMIG in murine serum. Adapted from Casal, et. al. [28].  
 
In order to corroborate the interaction of huMIG with anti-huMIG IgG deployed on the 
immunoHFET sensor surface, ELISAs were completed with a kit purchased from R& D Systems 
(Minneapolis, MN), the results of which can be seen in Figure 8 [28].  
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 Figure 8: ELISA Corroboration for detection of huMIG in murine serum. Adapted 
from Casal, et. al. [28]. 
 
CXCL9 Detection in Human Renal Transplant Recipient Urine 
Three-terminal current-voltage characteristics were measured as described previously.  
Preliminary immunoHFET sensor response to urine samples from both a rejecting and a non-
rejecting patients.   Figure 9 shows early electrical measurements for urine samples from one 
rejecting patient (patient 4) and one non-rejecting patient (patient 5) as compared to baseline 
measurements (initially blinded to patient allograft status). 
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 Figure 9: CXCL9 detection in urine of renal transplant patients.  
 
As clinical samples were collected, more sensor testing was completed, however issues 
began to arise with the results being obtained.   Triplicates of each test were completed for one 
rejecting and two non-rejecting patient samples.   Table 1 shows the average percent change in 
signal along with the standard deviation between triplicates.    
 
Table 1: Sensor Testing Data 
Patient Rejection Status Average Percent Change in Signal Standard Deviation 
13 Non-Rejecting 60% 11.65 
15 Rejecting 53% 11.95 
18 Non-Rejecting 52% 36.86 
 
Throughout all testing, one sensor was utilized and subjected to surface modification for 
each test performed.  The act of stripping molecules from the surface of the immunoHFET and 
re-oxidizing the AlGaN surface via inductively coupled plasma (ICP) reactive ion etching may 
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have surface damaging effects.   When performed a minimal number of times, ICP at 75 Watts 
and 700mTorr for 30 seconds would cause negligible damage to the surface, however the sensor 
used throughout testing had undergone countless iterations of this process and was likely to have 
accrued damage over the past years of testing.  
As shown by Fang, et. al., if damage free etching is desired, photoenhanced chemical 
(PEC) wet etching would be the most effective technology for surface functionalization, while 
hybrid ICP/PEC etching can be used for applications requiring high etch rate and damage-free 
surfaces [23].   However moving forward, surface damage by etching will not be a concern as it 
is desired to move toward one-use disposable devices.  
 Another possibility for the introduction of error could be disregarding the use of 1% BSA 
sterile filtered in PBS in sensor testing.  This blocking buffer was used throughout ELISAs after 
deposition of capture antibody anti-huMIG in order to block the remaining binding surface from 
nonspecific binding of antibodies and also in the sensing of huMIG in murine serum (Figure 7).   
This reagent however was not used in sensor testing with human patient urine samples and may 
be the reasoning behind the lack of correlation between sensor data as compared to biopsy 
rejection status.  
 
ELISA Corroboration 
ELISAs were performed as described above in coordination with protocol provided by 
PeproTech, Inc. (Rocky Hill, NJ) in order to corroborate electrical sensor data.  The procedure 
provided by PeproTech, Inc. was explicitly followed including all reconstitution and storage 
methods.  The first set of ELISA data (patients 1-8, 9/19/2013) proved to be promising and can 
be seen in Figure 11 while initial standard absorbance readings can be found within Figure 10.  
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As compared to Figure 9, patient 4 (rejecting) showed increased levels of CXCL9 in the 
data obtained by ELISA while patient 5 (non-rejecting) did not.  Increased levels of CXCL9 seen 
for patients 1 and 2 also coordinate with rejection status as confirmed by biopsy.   
 
 
Figure 10: Initial MIG ELISA Standards 
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 Figure 11: ELISA Results for Patients 1-8 
 
After a successful first ELISA with the Peprotech kit, we began to see complications with 
the results.   Although protocol states that when stored at -20ºC, aliquots are stable for up to 2 
years, it can be seen in Figure 12 that as time passed, problems arose with the reagents and thus 
the results of the ELISA suffered.  Since the initial creation of the standards on 9/19/2013, the 
absorbances decreased and the avidin-HRP conjugate actually became unusable.   
Avidin-HRP was tested prior to ELISAs by adding 100µl to 100µl of ABTS substrate.  If 
no immediate color change occurred, streptavidin-HRP (1:2000 in diluent) was utilized with 
TMP/H2O2 substrate and sulfuric acid stop solution.  This occurred for the ELISA completed on 
11/21/2013, hence the vastly different absorbances.  
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 Figure 12: ELISA Standards (MIG) for each ELISA test performed  
 
Future Recommendations 
Bovine Serum Albumin in Sensor Testing 
 As discussed above, 1% BSA sterile filtered in PBS was utilized in detection of huMIG 
in murine serum, shown in Figure 7, to block non-specific binding after the deposition of 
primary anti-huMIG IgG antibodies.  This blocking buffer was not used in any other sensor 
testing, however it could be beneficial to know the effects of its use.  By going back and 
implementing the use of this blocking buffer in testing known concentrations of huMIG in PBS, 
we would be able to identify if this step indeed caused the issues seen in sensor testing. 
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ELISA Kit 
An ELISA kit and protocol from R & D Systems (Minneapolis, MN) was utilized by 
Casal et. al. to corroborate immunoHFET sensor data in PBS [7,28] and was also used by Hrick 
et. al. and shown to be successful in the detection of CXCL9 in human urine.  In moving forward 
with ELISA corroboration for sensor data, this same kit should be used as opposed to the less 
expensive kit purchased from Peprotech, Inc. (Rocky Hill, NJ).  Although there are only slight 
differences in reagents and protocol from the currently used kit, it is expected to provide much 
more appropriate results in human urine.  Renal transplant recipient urine samples should be re-
tested using this kit for corroboration with sensor data.  
 
Silane Film Thickness 
 The sensor used was not engineered to minimize analyte-to-channel distance and thus 
maximize sensitivity.  One key factor that affects this distance in immunoHFET construction is 
the choice of silane.  The sensor used throughout this work incorporates TEA in fabrication, 
which is a trivalent silane that is similar to (3-Aminopropyl)triethoxysilane (APTES).  In using a 
trivalent silane, it is expected that the height of the silane layer would be greater than the height 
when utilizing a monovalent silane because of the likelihood to form meshworks as shown in 
Figure 13a.   These meshworks arise as a result of APTES-type silane monomers having the 
ability to form infinite, cross-linked siloxane polymer lattices. 
Constructing the immunoHFET exploiting a monovalent silane with structure similar to 
aminopropyl dimethylethoxy silane (APDMES) would allow for a highly ordered monolayer to 
be formed.  APDMES-type silanes are unable to polymerize into extensive networks because of 
only being able to form siloxane dimers or linkages to oxides.  The decreased thickness of 
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monovalent APDMES as compared to trivalent APTES can be seen within Figure 14.  Moving 
forward, an APDMES-type silane with terminal aldehyde group should be considered in surface 
functionalization to move toward increased sensitivity.  
 
 
Figure 13: Conceptual illustration of APTES (a) and APDMES (b). 
 
 
Figure 14: Film thickness of trivalent (APTES) and monovalent (APDMES) silane 
polymer films. Adapted from Bhushan et al [25] 
 
Engineered Antibodies as Receptors 
 The work presented herein utilized intact IgG antibodies (~10-15nm, 150-170kDa) as 
immunoHFET affinity elements deployed on the sensing surface.  By reducing the size of the 
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receptor used in device construction, the distance from sensing channel to analyte would be 
decreased, thus increasing sensitivity.   
The isolation of specific epitope regions of an antibody is possible and would be likely to 
greatly decrease the distance from bound analyte to sensing channel of the immunoHFET device.  
Single-chain fragment variable antibody fragments (scFvs) are fused proteins made of the heavy 
and light variable chains of IgG antibodies and are approximately half the size of an intact IgG 
antibody at 5-6nm.  Single domain antibody fragments known as variable heavy-heavy (VHH) 
fragments are even smaller at 2-4nm [26].   
 
 
Figure 15: Depiction of intact IgG antibody as well as single-chain fragment variable (scFv) and variable 
heavy-heavy (VHH) fragmented antibodies adapted from Casal, et al. [28] 
  
 Both of these identified antibody fragment options retain full analyte recognition 
properties even though they have the possibility to be as small as 10% the mass of intact 
antibodies [26]. 
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 As discussed by Casal, et. al., there exists the possibility to further obviate the concerns 
of ion shielding for immunoFETs by altering the protein topography via scanning circular 
permutagenesis (CP) [27, 28].  CP connects the N- and C- termini of a protein via a peptide 
linker and allows for the introduction of newly placed N- and C- termini at a specified location in 
the protein sequence.  In doing so, it is possible to control the analyte-sensing channel distance as 
well as orientation as shown in Figure 16 [5].  The depictions in this figure show CP variants of 
scFvs covalently attached to the sensing surface at their N-terminus.  By this, it is possible to 
place the site of analyte binding at a controlled (either greater or lesser) proximity to the sensing 
surface.   Currently, the sensitivity for successful detection of huMIG in physiological conditions 
is present and for this reason, circular permutagenesis is not required however, if problems arise 
in obtaining appropriate sensitivity, the possibility exists.   
 
 
Figure 16: Circular Permutagenesis of a scFv Adapted from Gupta, et. al. [5]. 
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 The engineered antibody receptors suggested here suggest further control of the distance 
from sensing surface to bound analyte.  As previously discussed, the control of this distance 
should be useful in the optimization of sensor sensitivity and thus the ability to detect transplant 
rejection at an earlier stage in the immuno response.  
 
Conclusions 
This work takes the previous knowledge of immunoHFET feasibility to detect analytes in 
PBS and expands into physiological salt conditions.  We have presented the successful detection 
of the inflammatory chemokine CXCL9 in both murine serum as well as human urine from 
transplant patients using an immunoHFET modified with anti-CXCL9 IgG.  CXCL9 was 
detected in renal transplant urine in biologically relevant levels, corroborated with ELISA, and 
correlated with rejection by renal biopsy.  The presented work demonstrates preliminary results 
of the feasibility of immunoHFET sensor operation in physiologic buffers and represents an 
early step in the translation of this technology to human clinical applications. The immunoHFET 
design may be scalable to allow for the potential to provide real-time quantification and 
monitoring of inflammatory mediators, thus allowing for minimally invasive interrogation of 
graft status at the bedside. 
The continuance of testing in complex physiologic environments (transplant patient urine 
and serum) will allow for increased evidence of the feasibility of immunoHFET detection of 
analytes in in vivo conditions.  It is anticipated that when taking into consideration the use of 
BSA as a blocking buffer, similar results to preliminary testing (Figure 9) will be reached in 
testing samples from both patients undergoing acute rejection episodes as well as non-rejecting 
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patients.  The differential CXCL9 levels should be confirmed by ELISA with the use of a kit 
purchased from R & D Systems (Minneapolis, MN) and initially blinded to patient allograft 
status.   
Many areas of optimization exist within the composition of the immunoHFET device 
including the choice of receptor and polymer film used in fabrication.  The sensors used in 
preliminary studies were not engineered to minimize the analyte-to-sensing channel distance thus 
maximizing the sensitivity.  This critical parameter may be addressed by multiple means, 
including investigating the composition of the sensor interface and silane used as well as the use 
of antibody fragments or circular permuted antibodies as receptors.  Increasing the sensitivity of 
the immunoHFET allows for earlier detection of CXCL9 and therefore earlier indication of renal 
transplant rejection.  
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